Pyrexar Medical — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Pyrexar Medical, founded in 2008 and headquartered in Salt Lake City, Utah, is a private company commercializing hyperthermia therapy devices for oncology. Its core technology uses phased-array RF antennas to deliver localized, image-guided heat to tumors, a modality supported by Level 1 clinical evidence for several cancer types. While the company generates revenue from sales of certain systems internationally, its advanced BSD-2000 3D/MR platform, which integrates real-time MR thermometry, is not yet available in the U.S. market, representing a significant regulatory and commercial hurdle. Pyrexar's strategy is to position hyperthermia as a synergistic, low-toxicity adjunct to standard cancer care.

Oncology

Technology Platform

Focused radiofrequency (RF) hyperthermia delivery systems using phased-array antennas for deep regional heating, with advanced platforms integrating real-time MR thermometry for image-guided thermal therapy.

Opportunities

The primary opportunity is the U.S.

market entry for its advanced image-guided hyperthermia system, which would provide access to the world's largest oncology treatment market.

Additionally, growing clinical evidence and inclusion in treatment guidelines for cancers like sarcoma and cervical cancer could drive increased global adoption as an adjunct to standard therapy.

Risk Factors

Major risks include failure to obtain FDA clearance for U.S.

sales of its flagship BSD-2000 3D/MR system, slow clinical adoption and reimbursement challenges for an adjunctive therapy, and competition from other thermal ablation or therapy technologies.

Competitive Landscape

Pyrexar operates in the niche hyperthermia therapy market. It faces competition from other hyperthermia device manufacturers (e.g., Celsius42 GmbH, Oncotherm) and alternative thermal therapy technologies like high-intensity focused ultrasound (HIFU) for ablation. Its key differentiator is its deep regional heating capability combined with real-time MR thermometry.

More companies in Oncology (General) →More companies in United States →